The purpose of this study is to evaluate the role of coronary CT angiogram (CCTA) as a superior guide for the assessment of coronary artery plaque and guiding treatment decisions. The investigators also assess the impact of preventive cardiovascular drugs on the plaque to improve patient outcomes. Participants aged 18-80 years, at intermediate or high-risk for coronary artery disease, with non-obstructive plaque on initial CCTA, will be enrolled in this study. They will be randomized into Standard of Care (SOC) vs. Aggressive Therapy (AT) groups. Both groups will undergo dietary and lifestyle interventions. Follow-up will consist of blood tests and clinic visits at baseline, 9 months, and 18 months. The second CCTA will be performed at 18 months to assess the change in plaque burden, characteristics, ischemia and pericoronary/epicardial fat.

Start Date01 Mar 2024

Sponsor / Collaborator

University of Louisville

NL-OMON51414 / RecruitingPhase 2

IcoSApent ethyL to slow down aortic VAlve stenosis proGrEssion - SALVAGE

Start Date07 Jun 2023

Sponsor / Collaborator-

NCT06466278 / RecruitingPhase 2IIT

IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion

This study invastigates the effect of icosapent ethyl in patients with aortic valve stenosis.

Start Date01 Jun 2023

Sponsor / Collaborator-

100 Clinical Results associated with Icosapent Ethyl

100 Translational Medicine associated with Icosapent Ethyl

100 Patents (Medical) associated with Icosapent Ethyl

752

Literatures (Medical) associated with Icosapent Ethyl

07 Feb 2024·European heart journal

Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use

Article

Author: Gaba, Prakriti ; Bhatt, Deepak L ; Boden, William E

02 Jan 2024·Journal of the American Heart Association

Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States

Article

Author: Bellows, Brandon K ; Bhatt, Deepak L ; Miller, Michael ; Kolm, Paul ; Ballantyne, Christie M ; Boden, William E ; Bress, Adam P ; Brinton, Eliot A ; Jacobson, Terry A ; Philip, Sephy ; Derington, Catherine G ; Weintraub, William S ; Tardif, Jean-Claude ; Steg, Gabriel ; Zhang, Zugui ; Dolman, Sarahfaye

Background:

In 3146 REDUCE‐IT USA (Reduction of Cardiovascular Events With Icosapent Ethyl Intervention Trial USA) participants, icosapent ethyl (IPE) reduced first and total cardiovascular events by 31% and 36%, respectively, over 4.9 years of follow‐up.

Methods and Results:

We used participant‐level data from REDUCE‐IT USA, 2021 US costs, and IPE costs ranging from $4.59 to $11.48 per day, allowing us to examine a range of possible medication costs. The in‐trial analysis was participant‐level, whereas the lifetime analysis used a Markov model. Both analyses considered value from a US health sector perspective. The incremental cost‐effectiveness ratio (incremental costs divided by incremental quality‐adjusted life‐years) of IPE compared with standard care (SC) was the primary outcome measure. There was incremental gain in quality‐adjusted life‐years with IPE compared with SC using in‐trial (3.28 versus 3.13) and lifetime (10.36 versus 9.83) horizons. Using an IPE cost of $4.59 per day, health care costs were lower with IPE compared with SC for both in‐trial ($29 420 versus $30 947) and lifetime ($216 243 versus $219 212) analyses. IPE versus SC was a dominant strategy in trial and over the lifetime, with 99.7% lifetime probability of an incremental cost‐effectiveness ratio <$50 000 per quality‐adjusted life‐year gained. At a medication cost of $11.48 per day, the cost per quality‐adjusted life‐year gained was $36 208 in trial and $4135 over the lifetime.

Conclusions:

In this analysis, at $4.59 per day, IPE offers better outcomes than SC at lower costs in trial and over a lifetime and is cost‐effective at $11.48 per day for conventional willingness‐to‐pay thresholds. Treatment with IPE should be strongly considered in US patients like those enrolled in REDUCE‐IT USA.

Registration:

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01492361.

01 Jan 2024·Biochimica et biophysica acta. Molecular and cell biology of lipids

Blood and tissue docosahexaenoic acid (DHA, 22:6n-3) turnover rates from Ahiflower® oil are not different than from DHA ethyl ester oil in a diet switch mouse model

Article

Author: Bazinet, Richard P ; Klievik, Brinley J ; Cumberford, Greg ; Smith, Mackenzie E ; Cisbani, Giulia ; Metherel, Adam H

Ahiflower® oil is high in α-linolenic and stearidonic acids, however, tissue/blood docosahexaenoic acid (DHA, 22:6n-3) turnover from dietary Ahiflower oil has not been investigated. In this study, we use compound-specific isotope analysis to determine tissue DHA synthesis/turnover from Ahiflower, flaxseed and DHA oils. Pregnant BALB/c mice (13-17 days) were placed on a 2 % algal DHA oil diet of high carbon-13 content (δ¹³C) and pups (n = 132) were maintained on the diet until 9 weeks old. Mice were then randomly allocated to a low δ¹³C-n-3 PUFA diet of either: 1) 4 % Ahiflower oil, 2) 4.35 % flaxseed oil or 3) 1 % fish DHA ethyl ester oil for 1, 3, 7, 14, 30, 60 or 120 days (n = 6). Serum, liver, adipose and brains were collected and DHA levels and δ¹³C were determined. DHA concentrations were highest (p < 0.05) in the liver and adipose of DHA-fed animals with no diet differences in serum or brain (p > 0.05). Based on the presence or absence of overlapping 95 % C.I.'s, DHA half-lives and synthesis/turnover rates were not different between Ahiflower and DHA diets in the liver, adipose or brain. DHA half-lives and synthesis/turnover rates from flaxseed oil were significantly slower than from the DHA diet in all serum/tissues. These findings suggest that the distinct Ahiflower oil n-3 PUFA composition could support tissue DHA needs at a similar rate to dietary DHA, making it a unique plant-based dietary option for maintaining DHA turnover comparably to dietary DHA.

100

News (Medical) associated with Icosapent Ethyl

26 Jun 2024

·www.fiercepharma.com

After stock crash and staff cuts, Amarin wins bid to revive Vascepa patent lawsuit

Amarin's shares have lost more than 95% of their value since the start of 2020. The loss of patent protection on Amarin’s sole commercial product Vascepa in 2020 has led to a roller coaster ride for the Dublin-based company over the past few years. But, now, the drugmaker is getting a fresh shot to challenge Hikma Pharmaceuticals’ generic version of its fish-oil-derived heart med in the lower courts. Tuesday, the U.S. Court of Appeals for the Federal Circuit revived (PDF) Amarin’s Vascepa patent lawsuit against generics giant Hikma. “Because Amarin’s allegations against Hikma plausibly state a claim for induced infringement, we reverse,” the court wrote in a legal filing this week. The case comes down to so-called “skinny labels,” which allow generic drug makers to get their copycat medicines approved for one or several—but not necessarily all—approved indications of their brand-name counterparts. The practice has proven controversial in Amarin and Hikma’s case, plus at least one other lawsuit involving Teva and GSK. Vascepa, also known as icosapent ethyl, won its first approval to reduce triglyceride levels in adults with severe hypertriglyceridemia in 2012. In 2019, the drug snagged a second FDA nod to reduce cardiovascular risks in adults with certain risk factors. Amarin originally sued Hikma in Delaware in 2020 after the generics maker in 2016 filed for approval of a copycat version of Vascepa that only included the severe hypertriglyceridemia nod and not the label language around cardio risks. The FDA approved Hikma’s Vascepa generic with a “skinny label” in May of 2020, court documents show. The appeals court this week ruled that Hikma’s generic label, press releases and marketing work may have prompted doctors to prescribe the copycat in violation of Amarin’s patents. The court specifically noted that Hikma publicly referred to its product as “generic Vascepa” without acknowledging the med’s label limitations. In turn, doctors were likely encouraged to prescribe the cheaper generic med for Vascepa’s full range of approved uses, the appeals court ruled. Amarin and Hikma did not immediately respond to Fierce Pharma’s request for comment. Chad Landmon, chair of the IP and FDA practice groups at law firm Axinn, Veltrop & Harkrider, noted that the Amarin-Hikma case is unusual because it concerns a launched generic, whereas most IP litigation occurs before approval and rollout. “I’m sure the decision is obviously a disappointment to Hikma, but I think also the generic and biosimilar industries probably are a little disappointed,” he told Fierce in an interview. Ever since Amarin’s U.S. patent loss on Vascepa, the company has been striving to make the most of the European market. Meanwhile, the market shift has resulted in much executive turnover and layoffs at the Irish company. Last summer, Amarin revealed that it would lay off its entire U.S. sales force and reduce its non-sales staff by 30%—amounting to roughly 120 out of 385 employees. The company also announced the appointment of Patrick Holt as its new CEO. Earlier this month, Holt said he was headed for the exit. Amarin’s new CEO will be Aaron Berg, who briefly served as Amarin’s interim chief executive last year following the abrupt departure of helmsman Karim Mikhail. Amarin's shares have lost more than 95% of their value since the start of 2020. Its shares haven't much budged in response to the latest legal development.

Executive ChangeDrug ApprovalPatent InfringementBiosimilar

04 Jun 2024

·www.biospace.com

Amarin Board of Directors Announces CEO Transition

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation PLC (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. “On behalf of the Company’s Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron as President & CEO,” said Odysseas Kostas, MD, the Chairman of the Board. “No one knows the company better than Aaron, and we look forward to him contributing meaningfully as CEO.” “As I begin this new role, my focus is clear – to find ways to deliver value for investors, and to maximize the potential of VASCEPA®/VAZKEPA for patients,” said Aaron Berg, President & CEO, Amarin. “I look forward to continuing to work with our Board of Directors and our tremendous team focusing on these priorities for the Company as we move forward.” Mr. Berg joined Amarin in November 2012 and has more than 30 years of biopharmaceutical industry experience. Mr. Berg initially served as Amarin’s Vice President, Marketing and Managed Care. He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018. Before joining Amarin, Mr. Berg served as President and Chief Executive Officer for Essentialis, Inc., a development stage pharmaceutical company where he led the company's work on triglyceride management. Prior to joining Essentialis, Mr. Berg served as Vice President of Marketing and Sales at Kos Pharmaceuticals (Kos), where he was instrumental in driving annual revenues approaching $1 billion. Mr. Berg worked at Kos until it was acquired by Abbott Laboratories in December 2006 for $3.7 billion. About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.  Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the potential for VASCEPA (marketed as VAZKEPA in Europe); beliefs about icosapent ethyl (IPE)’s role concerning appropriate patients suffering from cardiovascular disease (CVD) and potential population health impact, as well as general beliefs about the safety and effectiveness of VASCEPA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2023. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About Amarin communicates with its investors and the public using the company website ( ) and the investor relations website (amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Availability of Other Information About Amarin Investors and others should note that Amarin communicates with its investors and the public using the company website ( ), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact Information    Investor & Media Inquiries:    Mark Marmur  Amarin Corporation plc    PR@amarincorp.com

Executive ChangeAcquisition

28 May 2024

·www.biospace.com

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin’s exclusive distributor in the country -- DUBLIN, Ireland and BRIDGEWATER, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation PLC (NASDAQ:AMRN) today announces that the Greek Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and established cardiovascular disease, or diabetes and at least one other cardiovascular risk factor1. As in most European countries, cardiovascular diseases are the main cause of death in Greece2. Today’s approval – which marks the seventh national reimbursement of VAZKEPA® in Europe – provides eligible patients across Greece access to a new treatment option to reduce their cardiovascular risk and help improve their overall heart health. “We are very pleased with this seventh national reimbursement for VAZKEPA® supporting our continued growth opportunity in Europe which is a testament to the strength of our scientific data and the value of our product for patients at-risk for a cardiovascular event,” said Patrick Holt, President & CEO of Amarin. To support the commercialization of VAZKEPA® in Greece, Amarin has entered into an exclusive agreement with Vianex S.A., one of the leading pharmaceutical companies in Greece celebrating its 100-year anniversary this year. Under the terms of the agreement, Vianex S.A. will be the sole and exclusive distributor of VAZKEPA® in the territory to import, register, distribute and commercialize the product. Amarin will be responsible for supplying finished product to Vianex at a transfer price paid to Amarin. Vianex will start commercializing VAZKEPA® in the course of the next weeks. Christos Papadopoulos, Senior Vice President and Head of Commercial Europe at Amarin, commented: “We look forward to working with Vianex in bringing our VAZKEPA® treatment to healthcare providers and patients across Greece. As one of the country’s leading pharmaceutical companies, Vianex has strong commercial capabilities and deep expertise in cardiology and cardiovascular risk management. Their capabilities and experience align well with the opportunity to successfully commercialize VAZKEPA® and its proven ability to reduce cardiovascular risk and improve outcomes for patients.” About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. About VIANEX S.A. VIANEX S.A. is a Greek pharmaceutical company, founded in 1971 by the Giannakopoulos’ family that has been involved with the pharmaceutical industry since 1924. Through its 100-year history, VIANEX produces, imports, markets, packages and distributes a large number of pharmaceuticals, covering various therapeutic classes. It has formed strategic partnerships and alliances with major pharmaceutical entities across the globe. VIANEX owns four state-of-the-art fully specialized Manufacturing Plants that guarantee outstanding production capabilities. It covers the entire spectrum of manufacturing activities while it continuously upgrades the range of services by investing in technological equipment. VIANEX has also been exporting registered products for over 20 years in 114 countries worldwide and is an approved supplier of the World Health Organization. Strategic planning, focus to quality, operational excellence and long-term experience have contributed to a leading position in the Greek Pharmaceutical market, based on a long-term effort, that passes from generation to generation and constantly focuses to the future. Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the potential for VASCEPA (marketed as VAZKEPA in Europe); beliefs about icosapent ethyl (IPE)’s role concerning appropriate patients suffering from cardiovascular disease (CVD) and potential population health impact, as well as general beliefs about the safety and effectiveness of VASCEPA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2023. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About Amarin communicates with its investors and the public using the company website ( ) and the investor relations website ( ), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact Information Investor & Media Inquiries: Mark Marmur Amarin Corporation plc PR@amarincorp.com 1 2European Commission – Greece Country Health Pro – access May 2024

Drug ApprovalLicense out/in

100 Deals associated with Icosapent Ethyl

External Link

KEGG	Wiki	ATC	Drug Bank
D01892	Icosapent Ethyl	C10AX	DB08887

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	US	Amarin Pharmaceuticals Ireland Ltd.	13 Dec 2019
Hypertriglyceridemia	US	Amarin Pharmaceuticals Ireland Ltd.	26 Jul 2012
Arteriosclerosis Obliterans	JP	Mochida Pharmaceutical Co., Ltd.	15 Oct 1998
Hyperlipidemias	JP	Mochida Pharmaceutical Co., Ltd.	05 Oct 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hodgkin's Lymphoma	Phase 3	US	Amarin Neuroscience Ltd.	01 Sep 2005
Hodgkin's Lymphoma	Phase 3	CA	Amarin Neuroscience Ltd.	01 Sep 2005
Huntington Disease	Phase 3	US	Amarin Neuroscience Ltd.	01 Sep 2005
Huntington Disease	Phase 3	CA	Amarin Neuroscience Ltd.	01 Sep 2005
Nonalcoholic Steatohepatitis	Phase 2	US	Mochida Pharmaceutical Co., Ltd.	01 Jun 2010
Nonalcoholic Steatohepatitis	Phase 2	PR	Mochida Pharmaceutical Co., Ltd.	01 Jun 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01492361 (REDUCE-IT, GlobeNewswire) Manual	Not Applicable	Cardiovascular Diseases	-	Icosapent Ethyl (IPE) (Lp(a) ≥50 mg/dL)	uqozinutgl(hvmoddvfjd) = osdyqjjrqi mjnbhobeym (bluurrinuk ) View more	Positive	06 Apr 2024
				Icosapent Ethyl (IPE) (Lp(a) <50 mg/dL)	uqozinutgl(hvmoddvfjd) = ntklzqmmfy mjnbhobeym (bluurrinuk ) View more
NCT01492361 (REDUCE-IT USA, Pubmed)	Phase 3	-	3,146	Icosapent Ethyl	duzlstsdjw(qgrcaizzhs) = uqznjmmxlc rjuwuzermn (jxfkqxuocp ) View more	-	02 Jan 2024
NCT01492361 (REDUCE-IT, GlobeNewswire) Manual	Phase 3	Cardiovascular Diseases \| Metabolic Syndrome	2,866	VASCEPA	hlvrpzkvdi(bwputzyuls): relative risk reduction = 29, P-Value = <0.0001; absolute risk reduction = 5.9 View more	Positive	12 Nov 2023
				placebo
NCT01492361 (REDUCE-IT, Pubmed)	Phase 3	Metabolic Syndrome	8,179	Icosapent ethyl 4 g/day	enotqepmdh(stwkdydaap) = bndarokhsm gonfiacxby (ktysmypybl )	Positive	03 Nov 2023
REDUCE-IT (ESC2023)	Not Applicable	-	-	Icosapent ethyl	cyrazmvawg(rnmuweoibj) = nmjhbxgovt nxattynpjk (gkvsohspgz, 1.8 - 8.7)	-	27 Aug 2023
				Placebo	cyrazmvawg(rnmuweoibj) = rcmgrxgxrm nxattynpjk (gkvsohspgz, 1.9 - 9.4)
NCT01492361 (REDUCE-IT, Pubmed)	Phase 3	Atrial Fibrillation	8,179	Icosapent Ethyl	yosedlxptp(acxyseztqi) = tbnzipmkih tygqfjdgfd (iilkocdvqy )	-	21 Feb 2023
				Placebo	yosedlxptp(acxyseztqi) = guvnudzqjz tygqfjdgfd (iilkocdvqy )
NCT04221217 (Pubmed) Manual	Phase 3	Hypertriglyceridemia	122	MND-2119 (2 g/day)	kezadtveji(pjyzmzdbyg) = txdbhnohfa unytkdupwu (wbranurano ) View more	Positive	11 Sep 2022
				MND-2119 (4 g/day)	kezadtveji(pjyzmzdbyg) = kkbcnowyyw unytkdupwu (wbranurano ) View more
NCT01492361 (REDUCE-IT, Pubmed)	Phase 3	Hypertriglyceridemia \| Cardiovascular Diseases	8,179	Icosapent ethyl	ldqkyvopbu(sivtchyfow) = there was a slight increase in atrial fibrillation hfsmsgxmyt (dtqlpskgfw ) View more	Positive	03 May 2022
				Placebo
NCT01047683 (CTgov)	Phase 3	Hypertriglyceridemia	229	AMR101 (ethyl icosapentate) - 2 g/day (AMR101 (Ethyl Icosapentate) - 2 g/Day)	bcwjsitfuu(nmlrtrfslu) = ftrbtxewpq nrvywlpnue (mrqmciugww, kvaelpmimt - dvaujevdsg) View more	-	25 Apr 2022
				AMR101 (ethyl icosapentate) - 4 g/day (AMR101 (Ethyl Icosapentate) - 4 g/Day)	bcwjsitfuu(nmlrtrfslu) = xxfniwwuyx nrvywlpnue (mrqmciugww, mvznmbngbp - qtmasblxkc) View more
NCT01492361 (REDUCE-IT \| REDUCE-IT PCI \| REDUCE-IT USA \| REDUCE-IT CABG, CTgov)	Phase 3	Hypertriglyceridemia \| Cardiovascular Diseases	8,179	Statin therapy+AMR101 (AMR101)	axkhncswnn(ksfdilikhz) = vracroyidy xukdrhfuop (zmvrsptknh, rjafoblcjm - xgzzdknyce) View more	-	14 Apr 2022
				Statin therapy+Placebo (Placebo)	axkhncswnn(ksfdilikhz) = zvjkenqopa xukdrhfuop (zmvrsptknh, czmapifoab - jhzemvewrw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis